Whistler Conference Centre Floorplan

Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2018
Here are the related meetings in 2021:
Antibodies and Vaccines as Drugs for COVID-19 (EK31)
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Antibodies as Drugs: Translating Molecules into Treatments (C1)
Organizer(s) Paul W. H. I. Parren and Erica Ollmann Saphire
February 25—March 1, 2018
Whistler Conference Centre • Whistler, BC Canada
Discounted Abstract Deadline: Oct 24, 2017
Abstract Deadline: Nov 21, 2017
Scholarship Deadline: Oct 24, 2017
Discounted Registration Deadline: Dec 19, 2017
Sponsored by Bioverativ Therapeutics, Genentech, Inc., ImmunoGen, Inc., Merck & Co., Inc., OncoMed Pharmaceuticals, Inc., Pfizer Inc. and Regeneron Pharmaceuticals, Inc.
Summary of Meeting:
Antibodies carry an enormous potential in prophylaxis and treatment of human disease. Antibody therapies may be divided into two distinct but highly related disciplines. First, antibodies can be elicited de novo using vaccines. Our understanding of what constitutes an effective antibody response at the molecular level and the science of eliciting such antibodies in vivo are progressing rapidly. Secondly, isolated antibodies represent powerful drugs when developed as biopharmaceuticals, as demonstrated by the ever-expanding list of approved molecules as well as by the large number of antibody products in development in a wide range of therapeutic areas. The antibody landscape is changing as the field has moved from empirical to knowledge-based, designer approaches for which understanding of mechanisms of action at the molecular level is critical. Translating such basic knowledge into novel products and applications requires scientists from many disciplines including structural and cellular immunology, biology, engineering, chemistry and medicine to interact closely. Consequently, the field of antibody-based vaccines and therapeutics has become an interface area where experts meet and work together. The 2018 Keystone Symposia antibodies conference aims to provide a platform for knowledge-sharing from the molecular to the systems level to navigate the newest developments and insights to prevent, treat and cure major human diseases.
View Scholarships/Awards
Antibodies carry an enormous potential in prophylaxis and treatment of human disease. Antibody therapies may be divided into two distinct but highly related disciplines. First, antibodies can be elicited de novo using vaccines. Our understanding of what constitutes an effective antibody response at the molecular level and the science of eliciting such antibodies in vivo are progressing rapidly. Secondly, isolated antibodies represent powerful drugs when developed as biopharmaceuticals, as demonstrated by the ever-expanding list of approved molecules as well as by the large number of antibody products in development in a wide range of therapeutic areas. The antibody landscape is changing as the field has moved from empirical to knowledge-based, designer approaches for which understanding of mechanisms of action at the molecular level is critical. Translating such basic knowledge into novel products and applications requires scientists from many disciplines including structural and cellular immunology, biology, engineering, chemistry and medicine to interact closely. Consequently, the field of antibody-based vaccines and therapeutics has become an interface area where experts meet and work together. The 2018 Keystone Symposia antibodies conference aims to provide a platform for knowledge-sharing from the molecular to the systems level to navigate the newest developments and insights to prevent, treat and cure major human diseases.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
The meeting will begin on Sunday, February 25 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, March 1 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, March 2 in order to fully experience the meeting.
SUNDAY, FEBRUARY 25
MONDAY, FEBRUARY 26
TUESDAY, FEBRUARY 27
WEDNESDAY, FEBRUARY 28
THURSDAY, MARCH 1
FRIDAY, MARCH 2
Conference Program Print | View meeting in 12 hr (am/pm) time
The meeting will begin on Sunday, February 25 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, March 1 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, March 2 in order to fully experience the meeting.
SUNDAY, FEBRUARY 25
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.
08:00—09:00
Welcome and Keynote Address
*
Paul W. H. I. Parren,
Leiden University Medical Center, Netherlands
*
Erica Ollmann Saphire,
La Jolla Institute for Immunology, USA
*
David I. Watkins,
University of Miami, USA
Dennis R. Burton,
The Scripps Research Institute, USA
Molecular Vaccine Design Guided by Human Anti-Viral Antibodies
Molecular Vaccine Design Guided by Human Anti-Viral Antibodies
09:00—11:30
Protective Antibody Responses
*
David I. Watkins,
University of Miami, USA
George Georgiou,
University of Texas at Austin, USA
The Human Serological and BCR Antibody Repertoires in Cancer, Autoimmunity or following Vaccination
The Human Serological and BCR Antibody Repertoires in Cancer, Autoimmunity or following Vaccination
Coffee Break
Erica Ollmann Saphire,
La Jolla Institute for Immunology, USA
Systematic Analysis of Monoclonal Antibodies Against Ebola Virus GP Defines Features that Contribute to Protection
Systematic Analysis of Monoclonal Antibodies Against Ebola Virus GP Defines Features that Contribute to Protection
Antonio Lanzavecchia,
Vir Biotechnology, Inc., USA
Lessons from the Analysis of the Immune Response to P. falciparum
Lessons from the Analysis of the Immune Response to P. falciparum
Arthur S. Kim,
Washington University School of Medicine, USA
Short Talk: Identification of Protective Antibody Epitopes on the Eastern Equine Encephalitis Virus Envelope Protein
Short Talk: Identification of Protective Antibody Epitopes on the Eastern Equine Encephalitis Virus Envelope Protein
Sarah Elliott,
Wistar Institute, USA
Short Talk: DNA-Encoded Monoclonal Antibody (DMAb) for Acute Prophylaxis Against Influenza
Short Talk: DNA-Encoded Monoclonal Antibody (DMAb) for Acute Prophylaxis Against Influenza
14:30—16:30
Workshop 1: Antibodies and Protection
*
Ann J. Hessell,
Oregon Health & Science University, USA
Tongqing Zhou,
NIAID, National Institutes of Health, USA
Structural Basis of Zika-Neutralizing Monoclonal Antibodies Elicited in Immunized Macaque Monkeys
Structural Basis of Zika-Neutralizing Monoclonal Antibodies Elicited in Immunized Macaque Monkeys
Brett W. Jagger,
Washington University, USA
Efficacy of Zika Virus Vaccines Against Zika Infection in Mice During Pregnancy
Efficacy of Zika Virus Vaccines Against Zika Infection in Mice During Pregnancy
Laura A. Powell,
Vanderbilt University, USA
Cross-Reactive and Potently Neutralizing Antibody Response in a Donor Naturally Infected with Ross River Virus
Cross-Reactive and Potently Neutralizing Antibody Response in a Donor Naturally Infected with Ross River Virus
Natasha D. Durham,
Tufts University, USA
Neutralizing Antibodies Remodel the Conformational Landscape of Ebola GP
Neutralizing Antibodies Remodel the Conformational Landscape of Ebola GP
Hideki Hasegawa,
National Institute of Infectious Diseases, Japan
Enhancement of Anti-Viral Effects of an Intranasal Inactivated Influenza Vaccine-Derived Broadly Neutralizing Antibody by IgA Polymerization
Enhancement of Anti-Viral Effects of an Intranasal Inactivated Influenza Vaccine-Derived Broadly Neutralizing Antibody by IgA Polymerization
Bryan Briney,
The Scripps Research Institute, USA
Exceptionally Deep Antibody Repertoire Sequencing to Guide mAb Discovery and Development
Exceptionally Deep Antibody Repertoire Sequencing to Guide mAb Discovery and Development
Ron Diskin,
Weizmann Institute of Science, Israel
Targeting TfR1-Tropic Arenaviruses at their Achilles Heel: Structure-Based Rational Design of Universal Immunotherapy
Targeting TfR1-Tropic Arenaviruses at their Achilles Heel: Structure-Based Rational Design of Universal Immunotherapy
Matthijs M. Jore,
Radboud University Medical Center, Netherlands
Engineered Antibodies Against Plasmodium Transmission from Man to Mosquito
Engineered Antibodies Against Plasmodium Transmission from Man to Mosquito
17:00—19:00
From Molecules to Vaccines
*
Erica Ollmann Saphire,
La Jolla Institute for Immunology, USA
Nancy L. Haigwood,
Oregon Health & Science University, USA
Antibody-Based HIV Therapeutics: "Hit Early, Hit Hard"
Antibody-Based HIV Therapeutics: "Hit Early, Hit Hard"
James E. Crowe, Jr.,
Vanderbilt University Medical Center, USA
Genetic and Structural Basis for Virus Neutralization by Human Antibodies
Genetic and Structural Basis for Virus Neutralization by Human Antibodies
Robert F. Garry,
Tulane University Health Sciences Center, USA
Antibody Treatment of Lassa Virus: From the Field to the Lab and Back
Antibody Treatment of Lassa Virus: From the Field to the Lab and Back
Ruoke Wang,
Tsinghua University, China
Short Talk: Delineating Antibody Recognition Against Envelope Protein of Zika Virus during Natural Infection
Short Talk: Delineating Antibody Recognition Against Envelope Protein of Zika Virus during Natural Infection
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:45
Antibodies as Biopharmaceuticals
Janine Schuurman,
Genmab B.V., Netherlands
Therapeutic Antibody Panorama: Highways, Scenic Routes and Dead-Ends
Therapeutic Antibody Panorama: Highways, Scenic Routes and Dead-Ends
Karl Dane Wittrup,
Massachusetts Institute of Technology, USA
Principles of Effective Antibody Therapeutics
Principles of Effective Antibody Therapeutics
Coffee Break
Marie H. Kosco-Vilbois,
AC Immune, Switzerland
Creating Molecules that Succeed in the Clinic
Creating Molecules that Succeed in the Clinic
Emma M. Lees,
Bristol Myers Squibb, USA
JTX-2011: Mechanism of Action of an Agonist Antibody Targeting ICOS
JTX-2011: Mechanism of Action of an Agonist Antibody Targeting ICOS
*
Ira Mellman,
Genentech, Inc., USA
Antibodies in Cancer Immunotherapy
Antibodies in Cancer Immunotherapy
Cory Brooks,
California State University, Fresno, USA
Short Talk: Glycosylation of MUC1 Influences the Binding of a Therapeutic Antibody by Altering the Conformational Equilibrium of the Antigen
Short Talk: Glycosylation of MUC1 Influences the Binding of a Therapeutic Antibody by Altering the Conformational Equilibrium of the Antigen
Alexander W. Koch,
Novartis Institutes for BioMedical Research, USA
Short Talk: Targeting Coagulation Factor XI (FXI) for Thrombosis Prevention
Short Talk: Targeting Coagulation Factor XI (FXI) for Thrombosis Prevention
17:00—19:15
Antibody Fc-Mediated Mechanisms I
*
Pierre Bruhns,
Institut Pasteur, France
Pamela J. Bjorkman,
California Institute of Technology, USA
Structural Studies of Antibody and Receptor Binding to HIV-1 Env
Structural Studies of Antibody and Receptor Binding to HIV-1 Env
Jan Terje Andersen,
Oslo University Hospital, Norway
HERA: A Human Endothelial Cell-Based Recycling Assay for Screening of FcRn Targeted Molecules
HERA: A Human Endothelial Cell-Based Recycling Assay for Screening of FcRn Targeted Molecules
Jeffrey S. Miller,
University of Minnesota, USA
Strategies to Use Trispecific Killer Engagers to Make NK Cells Antigen Specific
Strategies to Use Trispecific Killer Engagers to Make NK Cells Antigen Specific
Julie M. Fox,
Washington University, USA
Short Talk: Antibody Therapy Reduces Chikungunya Virus Disease through an FcgR-Dependent Mechanism
Short Talk: Antibody Therapy Reduces Chikungunya Virus Disease through an FcgR-Dependent Mechanism
James A. Ernst,
Genentech, Inc., USA
Short Talk: Optimizing Antibodies for Targeting the Tau Protein for Alzheimer's Disease and Other Tauopathies
Short Talk: Optimizing Antibodies for Targeting the Tau Protein for Alzheimer's Disease and Other Tauopathies
19:15—20:15
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:15
Antibody Fc-Mediated Mechanisms II
*
Marjolein van Egmond,
VU University Medical Center, Netherlands
Paul W. H. I. Parren,
Leiden University Medical Center, Netherlands
Complement Activation at the Molecular Level
Complement Activation at the Molecular Level
Suzan Huberdina Maria Rooijakkers,
University Medical Center Utrecht, Netherlands
EMBO Young Investigator Lecture: Antibody-Mediated Killing of Bacteria by Complement
EMBO Young Investigator Lecture: Antibody-Mediated Killing of Bacteria by Complement
Coffee Break
Galit Alter,
MIT and Harvard University, USA
Correlate Guided Approaches to Develop Antibodies Against Ebola Virus Infection
Correlate Guided Approaches to Develop Antibodies Against Ebola Virus Infection
Pierre Bruhns,
Institut Pasteur, France
Analyses of Single Ab-Secreting Cells using Droplet Microfluidics
Analyses of Single Ab-Secreting Cells using Droplet Microfluidics
David P. Humphreys,
UCB Pharma, UK
Short Talk: On Target Hexamerisation of IgG1 Driven by a Mutant form of IgM Tail-Piece C-Terminal Fusion
Short Talk: On Target Hexamerisation of IgG1 Driven by a Mutant form of IgM Tail-Piece C-Terminal Fusion
Dieke J. van Rees,
Sanquin Research and Landsteiner Laboratory, Netherlands
Short Talk: Sodium Stibogluconate in Conjunction with CD47-SIRP Checkpoint Blockade Enables Rituximab-Mediated Killing of B Lymphoma Cells by Neutrophils
Short Talk: Sodium Stibogluconate in Conjunction with CD47-SIRP Checkpoint Blockade Enables Rituximab-Mediated Killing of B Lymphoma Cells by Neutrophils
14:30—16:30
Workshop 2: Therapeutic Antibodies
- Structural aspects of antibodies, novel insights
- Novel therapeutic antibody formats
- Novel antibody technologies
- From target to therapy
- Newly approved and upcoming antibody therapeutics
*
Ida Hiemstra,
Genmab, Netherlands
*
Devin Sok,
International AIDS Vaccine Initiative, USA
Non-Human Primate Pharmacokinetics of HIV Broadly Neutralizing Antibodies Isolated from Cow Immunizations
Non-Human Primate Pharmacokinetics of HIV Broadly Neutralizing Antibodies Isolated from Cow Immunizations
Amarendra Pegu,
NIAID, National Institutes of Health, USA
Trispecific Antibodies Mediate Highly Potent and Broad Neutralization of HIV and Confer Expanded Protection Against SHIV Infection in Macaques
Trispecific Antibodies Mediate Highly Potent and Broad Neutralization of HIV and Confer Expanded Protection Against SHIV Infection in Macaques
Sanjay Ram,
University of Massachusetts, USA
Potentiation of Efficacy of a Candidate Immunotherapeutic Anti-Neisseria Gonorrhoeae Antibody by Enhancing IgG Fc Hexamer Formation
Potentiation of Efficacy of a Candidate Immunotherapeutic Anti-Neisseria Gonorrhoeae Antibody by Enhancing IgG Fc Hexamer Formation
Nina G. Caculitan,
Genentech, Inc., USA
Discovery of the Determinants of Antibody-Drug Conjugate Efficacy and a Novel Resistance Mechanism to Anti-HER2 Therapeutics
Discovery of the Determinants of Antibody-Drug Conjugate Efficacy and a Novel Resistance Mechanism to Anti-HER2 Therapeutics
Jordana Griffiths,
University of Southampton, UK
Targeting OX40 in Cancer Immunotherapy
Targeting OX40 in Cancer Immunotherapy
John Engelhardt,
Bristol-Myers Squibb Company, USA
Next Generation Anti-CTLA-4 Antibodies
Next Generation Anti-CTLA-4 Antibodies
Ezio Bonvini,
MacroGenics, Inc, USA
Tailoring Cytolytic Activity, Proliferation and Cytokine Release via CD3 Engineering of DART® Molecules for Redirected T-cell Killing
Tailoring Cytolytic Activity, Proliferation and Cytokine Release via CD3 Engineering of DART® Molecules for Redirected T-cell Killing
Michael Johnston,
Queen's University Belfast, UK
Development of AMG 655 Conjugated Polymeric Nanoparticles Targeting Death Receptor 5 for the Treatment of Pancreatic Cancer
Development of AMG 655 Conjugated Polymeric Nanoparticles Targeting Death Receptor 5 for the Treatment of Pancreatic Cancer
17:00—19:00
Exploiting Effector Cell Responses
*
Pamela J. Bjorkman,
California Institute of Technology, USA
Sergio A. Quezada,
University College London, UK
Regulatory T Cells, Polymorphisms and Response to Checkpoint Blockade: From Mechanisms to Potential Biomarkers
Regulatory T Cells, Polymorphisms and Response to Checkpoint Blockade: From Mechanisms to Potential Biomarkers
Bertrand Routy,
Centre hospitalier de l’Université de Montréal, Canada
The Gut Microbiota as a Novel Predictor of Immune Checkpoint Inhibitors Response?
The Gut Microbiota as a Novel Predictor of Immune Checkpoint Inhibitors Response?
Marjolein van Egmond,
VU University Medical Center, Netherlands
Translating Antibody–Effector Cell Cross-Talk to Immunotherapy
Translating Antibody–Effector Cell Cross-Talk to Immunotherapy
Maria Mar Naranjo,
Centre National de la Recherche Scientifique, France
Short Talk: Key Immunomodulatory Role of Neutrophils in the Induction of Protective Immunity by Antiviral Monoclonal Antibodies
Short Talk: Key Immunomodulatory Role of Neutrophils in the Induction of Protective Immunity by Antiviral Monoclonal Antibodies
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:15
Novel Ways to Deliver Antibody Therapy
*
Janine Schuurman,
Genmab B.V., Netherlands
Ugur Sahin,
BioNTech AG, Germany
Antibody and mRNA-Based Therapeutics
Antibody and mRNA-Based Therapeutics
Mark Cobbold,
AstraZeneca, USA
Retargeting T Cells for Tumor Therapy
Retargeting T Cells for Tumor Therapy
Coffee Break
Markus Schmid,
University of Zurich, Switzerland
Paracrine Delivery of Therapeutic Proteins
Paracrine Delivery of Therapeutic Proteins
Johannes Lutz,
Curevac AG, Germany
mRNA-Encoded Antibodies for Passive Immunization
mRNA-Encoded Antibodies for Passive Immunization
Kalie Mix,
Sanofi, USA
Short Talk: Cytosolic Delivery of Antibodies
Short Talk: Cytosolic Delivery of Antibodies
Jeffrey J. Bunker,
University of Chicago, USA
Short Talk: Natural Polyreactive IgA Antibodies Coat the Intestinal Microbiota
Short Talk: Natural Polyreactive IgA Antibodies Coat the Intestinal Microbiota
17:00—18:45
From Molecules to the Clinic
*
Paul W. H. I. Parren,
Leiden University Medical Center, Netherlands
David E. Szymkowski,
Szymkowski David, USA
Exploring Novel Mechanisms of Action and Clinical Outcomes of Therapeutic Antibodies Fc-Engineered to Optimally Engage Fc Gamma RIIb
Exploring Novel Mechanisms of Action and Clinical Outcomes of Therapeutic Antibodies Fc-Engineered to Optimally Engage Fc Gamma RIIb
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.
*Session Chair †Invited, not yet responded.
We gratefully acknowledge support for this conference from:
Keystone Symposia thanks our Sponsors(s) for generously supporting this meeting:
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
|
We gratefully acknowledge the generous grant for this conference provided by:
We gratefully acknowledge additional support for this conference from:
![]() |
![]() |
![]() |
![]() |
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Corporate Relations, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |